Bowel Function After Minimally Invasive Urogynecologic Surgery
1 other identifier
interventional
72
1 country
1
Brief Summary
The purpose of this study is to assess the effect of a standardized postoperative bowel regimen of over-the-counter medications in subjects undergoing minimally invasive urogynecologic surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2009
CompletedFirst Submitted
Initial submission to the registry
January 5, 2010
CompletedFirst Posted
Study publicly available on registry
January 7, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2011
CompletedResults Posted
Study results publicly available
October 21, 2015
CompletedOctober 21, 2015
September 1, 2015
1.3 years
January 5, 2010
September 14, 2012
September 21, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to First Post-op Bowel Movement
The time to first post-operative bowel movement was measured in hours after surgery.
Within 1 week of surgery
Secondary Outcomes (2)
Pain Level Associated With First Postoperative Bowel Movement
Within 1 week of surgery
Consistency of First Postoperative Bowel Movement
Within 1 week of surgery
Study Arms (2)
Docusate
ACTIVE COMPARATORDocusate is the standard of care regimen
Bowel medications
EXPERIMENTALDocusate, Miralax, Metamucil wafers, Bisacodyl suppository
Interventions
Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
Eligibility Criteria
You may qualify if:
- Planning to be admitted to the hospital to undergo minimally-invasive urogynecologic surgery at Strong Memorial Hospital.
- Procedures may include:
- robot-assisted laparoscopic sacrocolpopexy
- sacrospinous ligament suspension
- uterosacral ligament suspension/paravaginal defect repair
- colpocleisis
- cystocele repair
- Additional procedures may include:
- hysterectomy
- adnexectomy
- culdoplasty
- minimally invasive sling procedure (TVT or TOT)
- periurethral collagen injections
- enterocele repair
You may not qualify if:
- Planning to undergo laparotomy.
- Undergoing rectocele or perineocele repair as part of surgery.
- Taking Miralax, laxatives, enemas, or suppositories daily, at the time of enrollment.
- Presence of a colostomy.
- Chronic kidney disease
- Insulin-dependent diabetes mellitus
- Known cardiac disease
- Gastric ulcers
- Difficulty swallowing or esophageal stricture
- Persistent nausea and vomiting
- Signs and symptoms consistent with bowel obstruction
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Rochester
Rochester, New York, 14642, United States
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Gunhilde Buchsbaum, Division Director Urogynecology
- Organization
- University of Rochester
Study Officials
- PRINCIPAL INVESTIGATOR
Gunhilde Buchsbaum, MD
University of Rochester
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 5, 2010
First Posted
January 7, 2010
Study Start
November 1, 2009
Primary Completion
February 1, 2011
Study Completion
February 1, 2011
Last Updated
October 21, 2015
Results First Posted
October 21, 2015
Record last verified: 2015-09